WHITE PAPERS
Specialty drug pipeline
Leading expert insights on specialty pharmacy medications
2024 delivered notable advancements in the FDA approval of treatments for rare diseases, with 43% of all novel drug approvals classified as first-in-class and 54% designated as orphan drugs. These approvals offer new hope to patients with conditions that previously had limited therapeutic options.
Here are 10 growth driver specialty medications we are closely tracking and educating our hospital and health system partners about.
Download reportHere are 10 growth driver specialty medications we are closely tracking and educating our hospital and health system partners about.
WHITE PAPERS
Innovating with specialty pharmacy clinical programs
Beyond HIV Viral Supression: The Role of Health System Specialty Pharmacists in Providing Comprehensive Care for People Living with HIV
Download paper >
Towards Eliminating Hepatitis C as a Public Health Threat in the United States
Download paper >